インスリンペンの世界市場：2019年～2023年

この市場について

2型糖尿病向けスマートインシュリンペンの開発に焦点を当てることによって、市場の成長が促進される可能性が高くなっています。企業は、先進技術を製品やサービスに組み込むことで、市場での成長に努めています。 Technavioのアナリストは、世界のインスリンペン市場が2023年までに約9％のCAGRで成長すると予測しています。

当レポートでは、世界のインスリンペン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場状況

• 市場のエコシステム
• 市場特性
• 市場セグメンテーション分析

第4章 市場規模

• 市場の定義
• 市場規模（2018年）
• 市場規模および予測（2018年～2023年）

第5章 ファイブフォース分析

• バイヤーの交渉力
• サプライヤーの交渉力
• 新規参入の脅威
• 代替品の脅威
• 競争相手の脅威
• 市場状況

第6章 市場セグメンテーション：製品別

• 市場セグメンテーション：製品別（2018年～2023年）
• 比較：製品別
• 再利用可能なインスリンペン
• 使い捨てインスリン・ペン
• 市場機会：製品別

第7章 顧客情勢

第8章 地域別景観

• 地域別セグメンテーション（2018年～2023年）
• 地域別比較
• 南北アメリカ
• 欧州・中東・アフリカ地域
• アジア太平洋地域
• 主要国
• 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

• 市場の成長要因
• 市場の課題

第11章 市場動向

• インスリンペンの販売促進のための戦略的パートナーシップの強化
• スマートインスリンペンへの関心の高まり
• 存在感の高まる糖尿病専門センター

第12章 ベンダー情勢

• 概要
• 創造的破壊の状況
• 競合シナリオ

第13章 ベンダー分析

• 対象ベンダー
• ベンダー分類
• ベンダーの市場ポジショニング
• BD
• Eli Lilly
• Novo Nordisk
• Sanofi

第14章 付録

• 調査方法
• 略語のリスト

第15章 TECHNAVIOについて

About this market:

The increasing focus on development of smart insulin pens for type 2 diabetes is likely to drive growth in the market. Companies are striving to grow in the market by incorporating advanced technologies into their products and services. Technavio's analysts have predicted that the insulin pens market will register a CAGR of close to 9% by 2023.

Market Overview:

Prevalence of diabetes cases across the globe

Growing incidence of diabetes have increased the demand for insulin pens in the market.

Increasing product recalls

Product recalls pose as a biggest threat to the market. Regulatory bodies and companies recalling products can impact the sales and a company's brand image.

For the detailed list of factors that will drive and challenge the growth of the insulin pens market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be concentrated and with the presence of few companies including BD and Eli Lilly the competitive environment is quite intense. Factors such as the increasing focus on development of smart insulin pens and the incidences of diabetes, will provide considerable growth opportunities to insulin pens manufactures. BD, Eli Lilly, Sanofi, and Novo Nordisk are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Reusable insulin pens - Market size and forecast 2018-2023
• Disposable insulin pens - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

• Rising strategic partnerships to boost sales of insulin pens
• Increasing focus on smart insulin pens
• Growing presence of diabetes specialty centers

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• BD
• Eli Lilly
• Novo Nordisk
• Sanofi

PART 14: APPENDIX

• Research methodology
• List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

• Exhibit 01: Global medical devices market
• Exhibit 02: Segments of global medical devices market
• Exhibit 03: Market characteristics
• Exhibit 04: Market segments
• Exhibit 05: Market definition - Inclusions and exclusions checklist
• Exhibit 06: Market size 2018
• Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
• Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
• Exhibit 09: Five forces analysis 2018
• Exhibit 10: Five forces analysis 2023
• Exhibit 11: Bargaining power of buyers
• Exhibit 12: Bargaining power of suppliers
• Exhibit 13: Threat of new entrants
• Exhibit 14: Threat of substitutes
• Exhibit 15: Threat of rivalry
• Exhibit 16: Market condition - Five forces 2018
• Exhibit 17: Product - Market share 2018-2023 (%)
• Exhibit 18: Comparison by product
• Exhibit 19: Reusable insulin pens - Market size and forecast 2018-2023 ($ millions)
• Exhibit 20: Reusable insulin pens - Year-over-year growth 2019-2023 (%)
• Exhibit 21: Disposable insulin pens - Market size and forecast 2018-2023 ($ millions)
• Exhibit 22: Disposable insulin pens - Year-over-year growth 2019-2023 (%)
• Exhibit 23: Market opportunity by product
• Exhibit 24: Customer landscape
• Exhibit 25: Market share by geography 2018-2023 (%)
• Exhibit 26: Geographic comparison
• Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
• Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
• Exhibit 29: Top 3 countries in Americas
• Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
• Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
• Exhibit 32: Top 3 countries in EMEA
• Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
• Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
• Exhibit 35: Top 3 countries in APAC
• Exhibit 36: Key leading countries
• Exhibit 37: Market opportunity
• Exhibit 38: Diabetes and prediabetes cases in the US in 2015
• Exhibit 39: Percentage of adults with diabetes aged between 20 and 79 years old in Europe in 2015
• Exhibit 40: Product launches and market impact analysis
• Exhibit 41: Insulin pens recall
• Exhibit 42: Impact of drivers and challenges
• Exhibit 43: Focus on strategic partnerships
• Exhibit 44: Vendor landscape
• Exhibit 45: Landscape disruption
• Exhibit 46: Vendors covered
• Exhibit 47: Vendor classification
• Exhibit 48: Market positioning of vendors
• Exhibit 49: BD - Vendor overview
• Exhibit 50: BD - Business segments
• Exhibit 51: BD - Organizational developments
• Exhibit 52: BD - Geographic focus
• Exhibit 53: BD - Segment focus
• Exhibit 54: BD - Key offerings
• Exhibit 55: Eli Lilly - Vendor overview
• Exhibit 56: Eli Lilly - Business segments
• Exhibit 57: Eli Lilly - Organizational developments
• Exhibit 58: Eli Lilly - Geographic focus
• Exhibit 59: Eli Lilly - Segment focus
• Exhibit 60: Eli Lilly - Key offerings
• Exhibit 61: Novo Nordisk - Vendor overview
• Exhibit 62: Novo Nordisk - Business segments
• Exhibit 63: Novo Nordisk - Organizational developments
• Exhibit 64: Novo Nordisk- Geographic focus
• Exhibit 65: Novo Nordisk - Segment focus
• Exhibit 66: Novo Nordisk - Key offerings
• Exhibit 67: Sanofi - Vendor overview
• Exhibit 68: Sanofi - Business segments
• Exhibit 69: Sanofi - Organizational developments
• Exhibit 70: Sanofi - Geographic focus
• Exhibit 71: Sanofi - Segment focus
• Exhibit 72: Sanofi - Key offerings